Targeting MET
Are you interested in learning more about a clinical trial program investigating the inhibition of oncogenic signaling caused by MET (gene) alterations?
LEARN MORE ABOUT OUR CLINICAL TRIALSGrounded in Science and born of boundless curiosity, EMD Serono’s clinical trials have enrolled thousands globally to change the cancer care landscape.
Are you interested in learning more about a clinical trial program investigating the inhibition of oncogenic signaling caused by MET (gene) alterations?
LEARN MORE ABOUT OUR CLINICAL TRIALS
Are you interested in learning more about a clinical trial program investigating the potential anticancer effect of inhibiting the DNA damage response (DDR) pathway?
LEARN MORE ABOUT OUR CLINICAL TRIALS
Are you interested in learning more about a clinical trial investigating the potential to enhance the activity of definitive therapy for LA SCCHN through antagonism of Inhibitor of Apoptosis Proteins (IAP)?
LEARN MORE ABOUT THIS CLINICAL TRIALTrilynX is a trademark of Merck KGaA, Darmstadt, Germany or its affiliates.
Abbreviations:
LA SCCHN, locally advanced squamous cell carcinoma of the head and neck; MET, mesenchymal
epithelial transition factor.